

HARM REDUCTION STRATEGIES

Gabriela Williams, PharmD, BCPS, BCPP
Psychiatric Clinical Pharmacy Specialist
Eskenazi Health, Indianapolis, IN
June 12, 2019

Disclosure

Gabriela Williams has nothing to disclose
in relation to this presentation.



Harm Reduction

- Philosophy that identifies the reality of drug use and focuses on the reduction of harmful consequences
 - Death
 - HIV
 - Hepatitis C
 - Criminal liability
 - Incarceration
- Opportunities to reduce morbidity and mortality associated with opioid use disorder

Harm Reduction Strategies

- Overdose education
- Naloxone
- Syringe service programs
- Supervised injection sites



Overdose Education

- ANY patient using opioids, family, friends, loved ones, etc.
- High risk individuals:
 - More than 100mg of oral morphine equivalents/day
 - History of overdose
 - Recent release from controlled environments (jail, inpatient treatment, etc.)
 - Concurrent use of other substances
- Recognition of overdose, appropriate response, naloxone administration

Naloxone

- Opioid antagonist which rapidly reverses the effects of opioids
 - Quick onset of activity
 - Duration of action ~ 30 – 90 minutes
- Multiple routes of administration: IV, IM, subcutaneous, intranasal, inhalation
- Intranasal and intramuscular administration as effective and safe option within the community

Intranasal Naloxone Kit

- 2 mucosal atomizer devices
- 2 naloxone 1 mg/ml (2ml)
- 1 Laerdal face shield
- 1 pair nitrile gloves
- 1 opioid safety brochure
- 1 intranasal naloxone kit brochure
- 1 blue zippered pouch



Intramuscular Naloxone Kit

- Two 3 ml, 25g, 1-inch syringes
- Two .4 mg/ml vials of naloxone
- 1 Laerdal face shield
- 1 pair nitrile gloves
- 2 alcohol pads
- 1 opioid safety brochure
- 1 intramuscular naloxone kit brochure
- 1 black zippered pouch



Naloxone Nasal Spray (4 mg)

Carton/box contains:

- Two 4 mg naloxone nasal sprays (each spray includes a Quick Start Guide)
- 1 prescribing information and patient instructions for use



Naloxone Auto-Injector

Carton/box contains:

- 1 auto-injector trainer
- 2 naloxone 0.4 mg auto-injectors
- 1 prescribing info
- 2 instructions for use





Indiana Statewide Naloxone Standing Order

- Statewide standing order for naloxone
- Registered entities may dispense naloxone to anyone who wishes to carry it → no individual prescription needed
- 2018 statistics:
 - 277 registered entities
 - 15,570 intranasal naloxone kits
 - 691 auto-injector kits
 - 27,336 non-specified kits
- Find a naloxone provider: www.optin.in.gov

Syringe Service Programs

- Community-based programs that provide access to sterile needles and syringes free of cost
- Services offered: sterile syringes and syringe exchange, sterile water/supplies, immunizations, testing for infectious diseases, clothing/food/necessities, etc.
- Goals:
 - Reduce infection
 - Safe syringe disposal
 - Referrals to treatment


Indiana Syringe Service Programs

**Syringe Service
Program
Providing
Counties**

**Updated
7-18-2018-EC**

SSP Services

Allen
Clark
Fayette
Madison
Marion
Monroe
Scott
Tippecanoe
Wayne



Benefits of Syringe Service Programs

- Life-saving
- Decreased borrowing/lending of syringes
- Decreased reduction in HIV transmission
- Decreased reduction in HBV/HCV transmission
- Improved disposal practices
- Potential decreases in injection frequency
- Referral to treatment
- Improvements in multiple life outcomes:
 - Housing, income, family relationships, legal issues, etc.
- Cost savings



Supervised Injection Sites

- Supervised facilities where individuals may use intravenous drugs under medical supervision
 - Pre-obtained drugs
- Benefits:
 - Overdose/death reduction
 - Increased hygienic and safe injection techniques
 - Decreased syringe sharing
 - Engagement in addiction treatment
 - Infection reduction
- Approximately 100 supervised sites in 66 cities throughout 11 countries
- Philadelphia, New York City, San Francisco as key US cities

HARM REDUCTION STRATEGIES

Gabriela Williams, PharmD, BCPS, BCPP
Psychiatric Clinical Pharmacy Specialist
Eskenazi Health, Indianapolis, IN
May 23, 2018